<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453960</url>
  </required_header>
  <id_info>
    <org_study_id>Roberta Granese, MD, PhD</org_study_id>
    <nct_id>NCT00453960</nct_id>
  </id_info>
  <brief_title>Genistein and Endometrial Hyperplasia</brief_title>
  <official_title>Effect of Genistein on Endometrial Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to verify the anti-estrogenic activity of Genistein, on the &quot;non
      atypical endometrial hyperplasia&quot;, in premenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although isoflavones alone (example: Genistein) have weak estrogenic effects on endometrial
      stromal and glandular cells, it was demonstrated, in several research efforts, that in the
      presence of E2 they act as antiestrogens.

      Considered that endometrial hyperplasia is due to strong and extended estrogenic stimulation,
      not offset by a proportionate amount of progesterone, we suppose that genistein could be
      therapeutic in these cases inducing a decrease of the hyperplasia and a change from the
      proliferative to a secretory phase of the endometrium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery from endometrial hyperplasia</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differential expression of ER-a and ER-b in endometrial specimens</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Endometrial Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Genistein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genistein 54 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norethisterone Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norethisterone Acetate 10mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Genivis</intervention_name>
    <description>54 mg/day daily for 6 months</description>
    <arm_group_label>Genistein</arm_group_label>
    <other_name>Fosteum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethisterone Acetate</intervention_name>
    <description>tablets 10mg/day from day 16 to 25 of menstruation</description>
    <arm_group_label>Norethisterone Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablets daily for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women

          -  Age &gt; = 44 years

          -  Dysfunctional uterine bleeding

          -  No treatment with other hormonal drugs (estrogen, progesterone)

          -  No local or general pathology negatively influenced by administration of genistein or
             progesterone

          -  No intrauterine pathologies (polyps, myomas)

          -  A &quot;non atypical endometrial hyperplasia&quot;, confirmed by hysteroscopy with biopsy and
             histological examination

        Exclusion Criteria:

          -  All the other conditions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>44 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario D'Anna, prof.</last_name>
    <role>Study Director</role>
    <affiliation>menopause centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Menopause Centre, Department of Gynecology and Obstetrics, Policlinico Universitario &quot;G.Martino&quot;</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Kayisli UA, Aksu CA, Berkkanoglu M, Arici A. Estrogenicity of isoflavones on human endometrial stromal and glandular cells. J Clin Endocrinol Metab. 2002 Dec;87(12):5539-44.</citation>
    <PMID>12466350</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>December 18, 2008</last_update_submitted>
  <last_update_submitted_qc>December 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>University of Messina</name_title>
    <organization>University of Messina</organization>
  </responsible_party>
  <keyword>Endometrial hyperplasia</keyword>
  <keyword>Genistein</keyword>
  <keyword>Isoflavones</keyword>
  <keyword>dysfunctional uterine bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

